Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis Academic Article uri icon

Overview

MeSH Major

  • Antirheumatic Agents
  • Arthritis, Juvenile
  • Recombinant Fusion Proteins

abstract

  • Sustained improvements in clinical and laboratory measures of the articular and systemic manifestations of systemic JIA were achieved in >50% of rilonacept-treated patients over 2 years. Treatment with rilonacept had a substantial steroid-sparing effect and was generally well-tolerated.

publication date

  • August 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/art.38042

PubMed ID

  • 23754188

Additional Document Info

start page

  • 2486

end page

  • 96

volume

  • 65

number

  • 9